Arkolith/Insider Trading/AVIR/Form 4

Sommadossi Jean-Pierre

President, CEO, and Chairman, DirectorAtea Pharmaceuticals, Inc. (AVIR) · full profile →Form 4 · filed Feb 4, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)100K——390K
Jan 31, 2025Option exercise(M)173K——290K
Jan 31, 2025Tax withholding(F)89K$3.06$271K301K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)440K—$0440K
Jan 31, 2025Grant(A)100K—$0100K
Jan 31, 2025Option exercise(M)173K—$0173K

Transaction Codes

A
Grant / award
M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-013846) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Atea Pharmaceuticals, Inc.

Build

Ask your agent about AVIR insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000950170-25-013846"
Ask your agent
Use Arkolith to summarize insider buying and selling at Atea Pharmaceuticals, Inc.
over the last 90 days and cite the filings.